Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis.
Razia GaidaIlse TruterCharles A PetersPublished in: Southern African journal of infectious diseases (2020)
All patients completed bedaquiline treatment, indicating that the adverse effects did not require discontinuation of the drug. However, when pharmacological intervention is required for the management of adverse effects, care should be taken to ensure that there is minimal interaction with other TB drugs and a low risk of further adverse effects.
Keyphrases
- drug resistant
- multidrug resistant
- acinetobacter baumannii
- end stage renal disease
- mycobacterium tuberculosis
- healthcare
- chronic kidney disease
- ejection fraction
- newly diagnosed
- palliative care
- prognostic factors
- quality improvement
- patient reported outcomes
- adverse drug
- pseudomonas aeruginosa
- hiv aids
- pulmonary tuberculosis
- human immunodeficiency virus
- antiretroviral therapy
- patient reported